Effects of Serotonin Agonist Citalopram on Multimodal Esophageal Stimulation in Healthy Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

14 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-07-31

Study Completion Date

2012-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate the effect of citalopram, a selective serotonin reuptake inhibitor, on esophageal sensitivity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Citalopram on Chest Pain in Patients With Functional Chest Pain

NCT05735756

Functional Chest Pain

TERMINATED PHASE4

Specific Effects of Escitalopram on Neuroendocrine Response

NCT00150527

Healthy

COMPLETED

Emotional Processing in Healthy Volunteers in the Presence of an Investigational Anxiolytic

NCT01424384

Depressive Disorder and Anxiety Disorders

COMPLETED PHASE1

A Study of RO4995819 in Combination With Citalopram in Healthy Volunteers

NCT01367756

Healthy Volunteer

COMPLETED PHASE1

Effects of Intravenous (IV) Citalopram on Emotional Brain Activity in Healthy Young and Elderly Adults

NCT01216449

Healthy Young and Elderly Volunteers

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastroesophageal Reflux

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Citalopram

Administration of citalopram to assess the esophageal sensitivity in HV

Group Type ACTIVE_COMPARATOR

Citalopram

Intervention Type DRUG

40 mg citalopram intravenously

Placebo

Administration of placebo to assess the esophageal sensitivity in HV

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Saline solution

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Citalopram

40 mg citalopram intravenously

Intervention Type DRUG

Placebo

Saline solution

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HV aged between 18 - 60 years

Exclusion Criteria

* history of psychiatric disease or a positive first degree psychiatric family history
* pregnancy or lactation
* concomitant administration of any centrally activating medication (anti-depressive medication, hypnotics, sedatives, anxiolytics, …)
* medication affecting esophageal motility
* significant co-morbidities (neuromuscular, psychiatric, cardiovascular, pulmonary, endocrine, autoimmune, renal and hepatic)
* prior history of esophageal, gastric surgery or endoscopic anti-reflux procedure
* history of gastrointestinal disease

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes